Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease

Sumio Ohtsuki, Hirofumi Yamaguchi, Young Sook Kang, Satoko Hori, Tetsuya Terasaki

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The blood-brain barrier (BBB) expresses transporters that influence both dopaminergic neuronal function and drug therapy for Parkinson's disease (PD). The purpose of the present study was to clarify changes of transporter mRNA expression at the BBB in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a model of PD, in order to understand the pathophysiological role of BBB transport function in PD. At 7 d after MPTP treatment, mice showed a motor deficit and a loss of dopaminergic neurons. At the same time, Ltype amino acid transporter 1 (LAT1) mRNA expression in the brain capillary fraction of the MPTP-treated mice was significantly reduced by 62.6% compared with saline-treated mice, while no significant change was observed in the expression of glucose transporter 1, creatine transporter 1, taurine transporter, organic cation transporter 2, serotonin transporter, norepinephrine transporter and dopamine transporter. LAT1 mRNA expression in whole brain was not affected at 1, 3 and 5 d after the treatment, but was reduced by 46.3% at 7 d. LAT1 mediates the transport of large neutral amino acids, including tyrosine, as well as the PD-therapeutic drug levodopa, across the BBB. Our findings indicate that decreased LAT1 expression at the BBB in PD patients may adversely affect amino acid supply from the circulating blood and levodopa distribution into the brain.

Original languageEnglish
Pages (from-to)1250-1252
Number of pages3
JournalBiological and Pharmaceutical Bulletin
Volume33
Issue number7
DOIs
Publication statusPublished - 2010 Jul 16
Externally publishedYes

Fingerprint

Amino Acid Transport Systems
Blood-Brain Barrier
Parkinson Disease
Messenger RNA
Brain
Levodopa
Norepinephrine Plasma Membrane Transport Proteins
Neutral Amino Acids
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Serotonin Plasma Membrane Transport Proteins
Dopamine Plasma Membrane Transport Proteins
Facilitative Glucose Transport Proteins
Dopaminergic Neurons
Tyrosine
Cations
Therapeutics
Amino Acids
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Blood-brain barrier
  • Brain capillary
  • L-type amino acid transporter 1
  • Parkinson's disease
  • Transporter

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. / Ohtsuki, Sumio; Yamaguchi, Hirofumi; Kang, Young Sook; Hori, Satoko; Terasaki, Tetsuya.

In: Biological and Pharmaceutical Bulletin, Vol. 33, No. 7, 16.07.2010, p. 1250-1252.

Research output: Contribution to journalArticle

Ohtsuki, Sumio ; Yamaguchi, Hirofumi ; Kang, Young Sook ; Hori, Satoko ; Terasaki, Tetsuya. / Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease. In: Biological and Pharmaceutical Bulletin. 2010 ; Vol. 33, No. 7. pp. 1250-1252.
@article{7f6aa399bbe74e71b9d1e065c5325d28,
title = "Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease",
abstract = "The blood-brain barrier (BBB) expresses transporters that influence both dopaminergic neuronal function and drug therapy for Parkinson's disease (PD). The purpose of the present study was to clarify changes of transporter mRNA expression at the BBB in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a model of PD, in order to understand the pathophysiological role of BBB transport function in PD. At 7 d after MPTP treatment, mice showed a motor deficit and a loss of dopaminergic neurons. At the same time, Ltype amino acid transporter 1 (LAT1) mRNA expression in the brain capillary fraction of the MPTP-treated mice was significantly reduced by 62.6{\%} compared with saline-treated mice, while no significant change was observed in the expression of glucose transporter 1, creatine transporter 1, taurine transporter, organic cation transporter 2, serotonin transporter, norepinephrine transporter and dopamine transporter. LAT1 mRNA expression in whole brain was not affected at 1, 3 and 5 d after the treatment, but was reduced by 46.3{\%} at 7 d. LAT1 mediates the transport of large neutral amino acids, including tyrosine, as well as the PD-therapeutic drug levodopa, across the BBB. Our findings indicate that decreased LAT1 expression at the BBB in PD patients may adversely affect amino acid supply from the circulating blood and levodopa distribution into the brain.",
keywords = "Blood-brain barrier, Brain capillary, L-type amino acid transporter 1, Parkinson's disease, Transporter",
author = "Sumio Ohtsuki and Hirofumi Yamaguchi and Kang, {Young Sook} and Satoko Hori and Tetsuya Terasaki",
year = "2010",
month = "7",
day = "16",
doi = "10.1248/bpb.33.1250",
language = "English",
volume = "33",
pages = "1250--1252",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "7",

}

TY - JOUR

T1 - Reduction of L-type amino acid transporter 1 mRNA expression in brain capillaries in a mouse model of Parkinson's disease

AU - Ohtsuki, Sumio

AU - Yamaguchi, Hirofumi

AU - Kang, Young Sook

AU - Hori, Satoko

AU - Terasaki, Tetsuya

PY - 2010/7/16

Y1 - 2010/7/16

N2 - The blood-brain barrier (BBB) expresses transporters that influence both dopaminergic neuronal function and drug therapy for Parkinson's disease (PD). The purpose of the present study was to clarify changes of transporter mRNA expression at the BBB in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a model of PD, in order to understand the pathophysiological role of BBB transport function in PD. At 7 d after MPTP treatment, mice showed a motor deficit and a loss of dopaminergic neurons. At the same time, Ltype amino acid transporter 1 (LAT1) mRNA expression in the brain capillary fraction of the MPTP-treated mice was significantly reduced by 62.6% compared with saline-treated mice, while no significant change was observed in the expression of glucose transporter 1, creatine transporter 1, taurine transporter, organic cation transporter 2, serotonin transporter, norepinephrine transporter and dopamine transporter. LAT1 mRNA expression in whole brain was not affected at 1, 3 and 5 d after the treatment, but was reduced by 46.3% at 7 d. LAT1 mediates the transport of large neutral amino acids, including tyrosine, as well as the PD-therapeutic drug levodopa, across the BBB. Our findings indicate that decreased LAT1 expression at the BBB in PD patients may adversely affect amino acid supply from the circulating blood and levodopa distribution into the brain.

AB - The blood-brain barrier (BBB) expresses transporters that influence both dopaminergic neuronal function and drug therapy for Parkinson's disease (PD). The purpose of the present study was to clarify changes of transporter mRNA expression at the BBB in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a model of PD, in order to understand the pathophysiological role of BBB transport function in PD. At 7 d after MPTP treatment, mice showed a motor deficit and a loss of dopaminergic neurons. At the same time, Ltype amino acid transporter 1 (LAT1) mRNA expression in the brain capillary fraction of the MPTP-treated mice was significantly reduced by 62.6% compared with saline-treated mice, while no significant change was observed in the expression of glucose transporter 1, creatine transporter 1, taurine transporter, organic cation transporter 2, serotonin transporter, norepinephrine transporter and dopamine transporter. LAT1 mRNA expression in whole brain was not affected at 1, 3 and 5 d after the treatment, but was reduced by 46.3% at 7 d. LAT1 mediates the transport of large neutral amino acids, including tyrosine, as well as the PD-therapeutic drug levodopa, across the BBB. Our findings indicate that decreased LAT1 expression at the BBB in PD patients may adversely affect amino acid supply from the circulating blood and levodopa distribution into the brain.

KW - Blood-brain barrier

KW - Brain capillary

KW - L-type amino acid transporter 1

KW - Parkinson's disease

KW - Transporter

UR - http://www.scopus.com/inward/record.url?scp=77954491076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954491076&partnerID=8YFLogxK

U2 - 10.1248/bpb.33.1250

DO - 10.1248/bpb.33.1250

M3 - Article

C2 - 20606323

AN - SCOPUS:77954491076

VL - 33

SP - 1250

EP - 1252

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 7

ER -